Tags

Type your tag names separated by a space and hit enter

Crisaborole Ointment 2%: A Review in Mild to Moderate Atopic Dermatitis.
Am J Clin Dermatol. 2017 Dec; 18(6):837-843.AJ

Abstract

Crisaborole ointment 2% (Eucrisa™) is a novel, anti-inflammatory inhibitor of phosphodiesterase 4 (PDE4) that is available in the USA for the topical treatment of mild to moderate atopic dermatitis in patients aged ≥ 2 years. In two short-term (28 days), identically designed, multicentre, phase III studies in this patient population, topical therapy with crisaborole ointment 2% reduced disease severity and pruritus severity compared with vehicle, with the effect established early and sustained over the course of treatment. Improvements in the other signs of atopic dermatitis (erythema, exudation, excoriation, induration/papulation, and lichenification) were also seen. Crisaborole ointment 2% was generally well tolerated in the short-term studies, with its favorable safety profile maintained over the longer term (up to 52 weeks) in a multicentre, extension study. Most treatment-emergent adverse events (TEAEs) were of mild to moderate severity and considered unrelated to the study medication. Moreover, the incidence of application-site pain following short- and longer-term topical therapy with crisaborole ointment 2% was low. In conclusion, crisaborole ointment 2% is an effective and generally well tolerated new topical option for the management of mild to moderate atopic dermatitis in patients aged ≥ 2 years, with the potential to effectively treat this patient population over the longer term without the safety concerns associated with other current topical anti-inflammatory agents.

Authors+Show Affiliations

Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand. demail@springer.com.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

29076116

Citation

Hoy, Sheridan M.. "Crisaborole Ointment 2%: a Review in Mild to Moderate Atopic Dermatitis." American Journal of Clinical Dermatology, vol. 18, no. 6, 2017, pp. 837-843.
Hoy SM. Crisaborole Ointment 2%: A Review in Mild to Moderate Atopic Dermatitis. Am J Clin Dermatol. 2017;18(6):837-843.
Hoy, S. M. (2017). Crisaborole Ointment 2%: A Review in Mild to Moderate Atopic Dermatitis. American Journal of Clinical Dermatology, 18(6), 837-843. https://doi.org/10.1007/s40257-017-0327-4
Hoy SM. Crisaborole Ointment 2%: a Review in Mild to Moderate Atopic Dermatitis. Am J Clin Dermatol. 2017;18(6):837-843. PubMed PMID: 29076116.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Crisaborole Ointment 2%: A Review in Mild to Moderate Atopic Dermatitis. A1 - Hoy,Sheridan M, PY - 2017/10/28/pubmed PY - 2018/2/2/medline PY - 2017/10/28/entrez SP - 837 EP - 843 JF - American journal of clinical dermatology JO - Am J Clin Dermatol VL - 18 IS - 6 N2 - Crisaborole ointment 2% (Eucrisa™) is a novel, anti-inflammatory inhibitor of phosphodiesterase 4 (PDE4) that is available in the USA for the topical treatment of mild to moderate atopic dermatitis in patients aged ≥ 2 years. In two short-term (28 days), identically designed, multicentre, phase III studies in this patient population, topical therapy with crisaborole ointment 2% reduced disease severity and pruritus severity compared with vehicle, with the effect established early and sustained over the course of treatment. Improvements in the other signs of atopic dermatitis (erythema, exudation, excoriation, induration/papulation, and lichenification) were also seen. Crisaborole ointment 2% was generally well tolerated in the short-term studies, with its favorable safety profile maintained over the longer term (up to 52 weeks) in a multicentre, extension study. Most treatment-emergent adverse events (TEAEs) were of mild to moderate severity and considered unrelated to the study medication. Moreover, the incidence of application-site pain following short- and longer-term topical therapy with crisaborole ointment 2% was low. In conclusion, crisaborole ointment 2% is an effective and generally well tolerated new topical option for the management of mild to moderate atopic dermatitis in patients aged ≥ 2 years, with the potential to effectively treat this patient population over the longer term without the safety concerns associated with other current topical anti-inflammatory agents. SN - 1179-1888 UR - https://www.unboundmedicine.com/medline/citation/29076116/Crisaborole_Ointment_2:_A_Review_in_Mild_to_Moderate_Atopic_Dermatitis_ L2 - https://dx.doi.org/10.1007/s40257-017-0327-4 DB - PRIME DP - Unbound Medicine ER -